russjcardiolРоссийский кардиологический журналRussian Journal of Cardiology1560-40712618-7620«SILICEA-POLIGRAF» LLC10.15829/1560-4071-2017-3-72-76russjcardiol-1600Research ArticleМНЕНИЕ ПО ПРОБЛЕМЕOPINION ON THE ISSUEОСОБЕННОСТИ ДИАГНОСТИКИ И ЛЕЧЕНИЯ ИШЕМИЧЕСКОЙ БОЛЕЗНИ СЕРДЦА У ПАЦИЕНТОВ ПОЖИЛОГО И СТАРЧЕСКОГО ВОЗРАСТАTHE SPECIFICS OF ISCHEMIC HEART DISEASE MANAGEMENT IN ELDERLYБеляловФ. И.BelyalovF. I.fbelyalov@mail.ruИркутская государственная медицинская академия последипломного образованияРоссияIrkutsk State Medical Academy of Postgraduate EducationRussian Federation201725032017037276Copyright © Белялов Ф.И., 20172017Белялов Ф.И.Belyalov F.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://russjcardiol.elpub.ru/jour/article/view/1600

Ишемическая  болезнь  сердца  вносит значительный вклад в заболеваемость и смертность   населения. В статье  обсуждаются  особенности   диагностики и лечения хронической ишемической  болезни  сердца  у пациентов  старшего возраста. Ведение  таких пациентов  затрудняется частой  коморбидностью, снижением познавательных возможностей, повышением риска побочных эффектов  лекарств,  ограниченными ресурсами для выбора оптимального лечения.

Ischemic heart  disease impacts  greatly the morbidity and mortality of population. The  article  focuses   on  the  specifics  of  diagnostics   and  treatment of  chronic coronary heart disease in patients of older age. Management of this kind of patients is complicated  with comorbidity, cognition decline, increased risk of side effects, reduced range of treatment options.

ишемическая болезнь сердцапожилой возрастгериатрияischemic heart diseaseelderlygeriatricsReferencesVeledar E, Fazel R, Shaw L, et al. Analyzing recent trends in coronary heart disease (CHD) deaths among the elderly in the United States using data from official statistical sources. Med. Arch. 2010; 64(5): 281-3.Veledar E, Fazel R, Shaw L, et al. Analyzing recent trends in coronary heart disease (CHD) deaths among the elderly in the United States using data from official statistical sources. Med. Arch. 2010; 64(5): 281-3.Plassman BL, Langa KM, Fisher GG, et al. Prevalence of cognitive impairment without dementia in the United States. Ann. Intern. Med. 2008; 148(6): 427-34.Plassman BL, Langa KM, Fisher GG, et al. Prevalence of cognitive impairment without dementia in the United States. Ann. Intern. Med. 2008; 148(6): 427-34.Genders TSS, Steyerberg EW, Alkadhi H, et al. A clinical prediction rule for the diagnosis of coronary artery disease: validation, updating, and extension. Eur. Heart. J. 2011; 32(11): 1316-30.Genders TSS, Steyerberg EW, Alkadhi H, et al. A clinical prediction rule for the diagnosis of coronary artery disease: validation, updating, and extension. Eur. Heart. J. 2011; 32(11): 1316-30.Patel MR, Dai D, Hernandez AF, et al. Prevalence and predictors of nonobstructive coronary artery disease identified with coronary angiography in contemporary clinical practice. American Heart Journal. 2014; 167: 846-52.e2.Patel MR, Dai D, Hernandez AF, et al. Prevalence and predictors of nonobstructive coronary artery disease identified with coronary angiography in contemporary clinical practice. American Heart Journal. 2014; 167: 846-52.e2.Practice of Geriatrics by Edmund H. Duthie. 4rd edition. 2007. 681 p.Practice of Geriatrics by Edmund H. Duthie. 4rd edition. 2007. 681 p.Ban JE, Park HC, Park JS, et al. Electrocardiographic and electrophysiological characteristics of premature ventricular complexes associated with left ventricular dysfunction in patients without structural heart disease. Europace. 2013; 15(5): 735-41.Ban JE, Park HC, Park JS, et al. Electrocardiographic and electrophysiological characteristics of premature ventricular complexes associated with left ventricular dysfunction in patients without structural heart disease. Europace. 2013; 15(5): 735-41.European Society of Cardiology. 2013 ESC guidelines on the management of stable coronary artery disease. Eur. Heart. J. 2013; 34: 2949-3003.European Society of Cardiology. 2013 ESC guidelines on the management of stable coronary artery disease. Eur. Heart. J. 2013; 34: 2949-3003.Shreibati JB, Baker LC, Hlatky MA. Association of Coronary CT Angiography or Stress Testing With Subsequent Utilization and Spending Among Medicare Beneficiaries. JAMA. 2011; 306(19): 2128-36.Shreibati JB, Baker LC, Hlatky MA. Association of Coronary CT Angiography or Stress Testing With Subsequent Utilization and Spending Among Medicare Beneficiaries. JAMA. 2011; 306(19): 2128-36.Zeng W, Stason WB, Fournier S, et al. Benefits and costs of intensive lifestyle modification programs for symptomatic coronary disease in Medicare beneficiaries. American Heart Journal. 2013; 165(5): 785-92.Zeng W, Stason WB, Fournier S, et al. Benefits and costs of intensive lifestyle modification programs for symptomatic coronary disease in Medicare beneficiaries. American Heart Journal. 2013; 165(5): 785-92.Patel AV, Bernstein L, Deka A, et al. Leisure time spent sitting in relation to total mortality in a prospective cohort of US adults. Am. J. Epidemiol. 2010; 172: 419-29.Patel AV, Bernstein L, Deka A, et al. Leisure time spent sitting in relation to total mortality in a prospective cohort of US adults. Am. J. Epidemiol. 2010; 172: 419-29.Gellert C, Schüttker B, Brenner H. Smoking and all-cause mortality in older people: systematic review and meta–analysis. Arch. Intern. Med. 2012; 172: 837-44.Gellert C, Schüttker B, Brenner H. Smoking and all-cause mortality in older people: systematic review and meta–analysis. Arch. Intern. Med. 2012; 172: 837-44.Hsu PF, Sung SH, Cheng HM, et al. Association of Clinical Symptomatic Hypoglycemia With Cardiovascular Events and Total Mortality in Type 2 Diabetes: A nationwide population– based study. Diabetes Care. 2013; 36(4): 894-900.Hsu PF, Sung SH, Cheng HM, et al. Association of Clinical Symptomatic Hypoglycemia With Cardiovascular Events and Total Mortality in Type 2 Diabetes: A nationwide population– based study. Diabetes Care. 2013; 36(4): 894-900.Li Y, Hu Y, Ley SH, et al. Sulfonylurea Use and Incident Cardiovascular Disease Among Patients With Type 2 Diabetes: Prospective Cohort Study Among Women. Diabetes Care. 2014; 37: 3106-13.Li Y, Hu Y, Ley SH, et al. Sulfonylurea Use and Incident Cardiovascular Disease Among Patients With Type 2 Diabetes: Prospective Cohort Study Among Women. Diabetes Care. 2014; 37: 3106-13.Schramm TK, Gislason GH, Vaag A, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur. Heart J. 2011; 32: 1900-8.Schramm TK, Gislason GH, Vaag A, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur. Heart J. 2011; 32: 1900-8.Mogensen UM, Andersson C, Loldrup Fosbøl E, et al. Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality-a retrospective nationwide study. Diabetes Res. Clin. Pract. 2015; 107(1): 104-12.Mogensen UM, Andersson C, Loldrup Fosbøl E, et al. Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality-a retrospective nationwide study. Diabetes Res. Clin. Pract. 2015; 107(1): 104-12.Boekholdt S, Hovingh G, Mora S, et al. Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events: A Meta-Analysis of Statin Trials. J. Am. Coll. Cardiol. 2014; 64(5): 485-94.Boekholdt S, Hovingh G, Mora S, et al. Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events: A Meta-Analysis of Statin Trials. J. Am. Coll. Cardiol. 2014; 64(5): 485-94.Afilalo J, Duque G, Steele R, et al. Statins for Secondary Prevention in Elderly Patients: A Hierarchical Bayesian Meta-Analysis. J. Am. Coll. Cardiol. 2008; 51: 37-45.Afilalo J, Duque G, Steele R, et al. Statins for Secondary Prevention in Elderly Patients: A Hierarchical Bayesian Meta-Analysis. J. Am. Coll. Cardiol. 2008; 51: 37-45.Gransbo K, Melander O, Wallentin L, et al. Cardiovascular and Cancer Mortality in Very Elderly Post-Myocardial Infarction Patients Receiving Statin Treatment. J. Am. Coll. Cardiol. 2010; 55(13): 1362-9.Gransbo K, Melander O, Wallentin L, et al. Cardiovascular and Cancer Mortality in Very Elderly Post-Myocardial Infarction Patients Receiving Statin Treatment. J. Am. Coll. Cardiol. 2010; 55(13): 1362-9.2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. J Am Coll Cardiol. 2014; 63 (25 Pt B): 2889-934.2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. J Am Coll Cardiol. 2014; 63 (25 Pt B): 2889-934.Wenger NK, Lewis SJ, Herrington DM, et al. Outcomes of Using Highor Low-Dose Atorvastatin in Patients 65 Years of Age or Older with Stable Coronary Heart Disease. Ann. Intern. Med. 2007; 147: 1-9.Wenger NK, Lewis SJ, Herrington DM, et al. Outcomes of Using Highor Low-Dose Atorvastatin in Patients 65 Years of Age or Older with Stable Coronary Heart Disease. Ann. Intern. Med. 2007; 147: 1-9.Deedwania P, Stone PH, Bairey Merz CN, et al. Effects of Intensive Versus Moderate Lipid– Lowering Therapy on Myocardial Ischemia in Older Patients With Coronary Heart Disease. Circulation. 2007; 115(6): 700-7.Deedwania P, Stone PH, Bairey Merz CN, et al. Effects of Intensive Versus Moderate Lipid– Lowering Therapy on Myocardial Ischemia in Older Patients With Coronary Heart Disease. Circulation. 2007; 115(6): 700-7.Golomb BA, Evans MA, Dimsdale JE, et al. Effects of statins on energy and fatigue with exertion: Results from a randomized controlled trial. Arch. Intern. Med. 2012; 172(15): 1180-2.Golomb BA, Evans MA, Dimsdale JE, et al. Effects of statins on energy and fatigue with exertion: Results from a randomized controlled trial. Arch. Intern. Med. 2012; 172(15): 1180-2.Rothwell PM, Price JF, Fowkes FG, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. The Lancet. 2012; 379(982): 1602-12.Rothwell PM, Price JF, Fowkes FG, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. The Lancet. 2012; 379(982): 1602-12.Farland MZ, Peters CJ, Williams JD, et al. b-Blocker Use and Incidence of Chronic Obstructive Pulmonary Disease Exacerbations. Ann. Pharmacother. 2013; 47(5): 651-6.Farland MZ, Peters CJ, Williams JD, et al. b-Blocker Use and Incidence of Chronic Obstructive Pulmonary Disease Exacerbations. Ann. Pharmacother. 2013; 47(5): 651-6.Ni Y, Shi G, Wan H. Use of cardioselective β-blockers in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized, placebo-controlled, blinded trials. J. Int. Med. Res. 2012; 40(6): 2051-65.Ni Y, Shi G, Wan H. Use of cardioselective β-blockers in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized, placebo-controlled, blinded trials. J. Int. Med. Res. 2012; 40(6): 2051-65.Fox K, Ford I, Steg PG, et al. Ivabradine in Stable Coronary Artery Disease without Clinical Heart Failure. N. Eng.l J. Med. 2014; 371: 1091-9.Fox K, Ford I, Steg PG, et al. Ivabradine in Stable Coronary Artery Disease without Clinical Heart Failure. N. Eng.l J. Med. 2014; 371: 1091-9.Bonetti PO, Kaiser C, Zellweger MJ, et al. Long-Term Benefits and Limitations of Combined Antianginal Drug Therapy in Elderly Patients with Symptomatic Chronic Coronary Artery Disease. J. Cardiovasc. Pharmacol. Ther. 2005; 10: 29-37.Bonetti PO, Kaiser C, Zellweger MJ, et al. Long-Term Benefits and Limitations of Combined Antianginal Drug Therapy in Elderly Patients with Symptomatic Chronic Coronary Artery Disease. J. Cardiovasc. Pharmacol. Ther. 2005; 10: 29-37.Boden WE, O’Rourke RA, Teo KK, et al. Optimal Medical Therapy with or without PCI for Stable Coronary Disease. N. Eng.l J. Med., 2007; 356: 1503-16.Boden WE, O’Rourke RA, Teo KK, et al. Optimal Medical Therapy with or without PCI for Stable Coronary Disease. N. Eng.l J. Med., 2007; 356: 1503-16.Rana O, Moran R, O’Kane P, et al. Percutaneous Coronary Intervention in the Very Elderly (≥85 Years). Br. J. Cardiol. 2013; 20: 27-31.Rana O, Moran R, O’Kane P, et al. Percutaneous Coronary Intervention in the Very Elderly (≥85 Years). Br. J. Cardiol. 2013; 20: 27-31.Bainey KR, Selzer F, Cohen HA, et al. Comparison of Three Age Groups Regarding Safety and Efficacy of Drug-Eluting Stents (from the National Heart, Lung, and Blood Institute Dynamic Registry). The American journal of cardiology. 2012; 109(2): 195-201.Bainey KR, Selzer F, Cohen HA, et al. Comparison of Three Age Groups Regarding Safety and Efficacy of Drug-Eluting Stents (from the National Heart, Lung, and Blood Institute Dynamic Registry). The American journal of cardiology. 2012; 109(2): 195-201.Cantor WJ, Mehta SR, Yuan F, et al. Radial versus femoral access for elderly patients with acute coronary syndrome undergoing coronary angiography and intervention: insights from the RIVAL trial. American Heart Journal. 2015; 170(5): 880-6.Cantor WJ, Mehta SR, Yuan F, et al. Radial versus femoral access for elderly patients with acute coronary syndrome undergoing coronary angiography and intervention: insights from the RIVAL trial. American Heart Journal. 2015; 170(5): 880-6.de Belder A, de la Torre Hernandez JM, Lopez-Palop R, et al. A Prospective Randomized Trial of Everolimus–Eluting Stents Versus Bare-Metal Stents in Octogenarians: The XIMA Trial. J. Am. Coll. Cardiol. 2014; 63(14): 1371-5.de Belder A, de la Torre Hernandez JM, Lopez-Palop R, et al. A Prospective Randomized Trial of Everolimus–Eluting Stents Versus Bare-Metal Stents in Octogenarians: The XIMA Trial. J. Am. Coll. Cardiol. 2014; 63(14): 1371-5.Mangiacapra F, Ricottini E, Di Gioia G, et al. Comparison Among Patients ≥75 Years Having Percutaneous Coronary Angioplasty Using Drug-Eluting Stents Versus Bare Metal Stents. American Journal of Cardiology. 2015; 115: 1179-84.Mangiacapra F, Ricottini E, Di Gioia G, et al. Comparison Among Patients ≥75 Years Having Percutaneous Coronary Angioplasty Using Drug-Eluting Stents Versus Bare Metal Stents. American Journal of Cardiology. 2015; 115: 1179-84.Jin MC, Yoshinobu O, Nicolo P, et al. Comparison of Five-Year Outcome of Octogenarians Undergoing Percutaneous Coronary Intervention With Drug-Eluting Versus Bare–Metal Stents. The American journal of cardiology. 2010; 106(10): 1376-81.Jin MC, Yoshinobu O, Nicolo P, et al. Comparison of Five-Year Outcome of Octogenarians Undergoing Percutaneous Coronary Intervention With Drug-Eluting Versus Bare–Metal Stents. The American journal of cardiology. 2010; 106(10): 1376-81.Navarese EP, Tandjung K, Claessen B, et al. Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice. B.M.J. 2013; 347: f6530.Navarese EP, Tandjung K, Claessen B, et al. Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice. B.M.J. 2013; 347: f6530.Bangalore S, Kumar S, Fusaro M, et al. Short and Long-Term Outcomes with Drug Eluting and Bare Metal Coronary Stents. Circulation. 2012; 125(23): 2873-91.Bangalore S, Kumar S, Fusaro M, et al. Short and Long-Term Outcomes with Drug Eluting and Bare Metal Coronary Stents. Circulation. 2012; 125(23): 2873-91.Zhang Z, Kolm P, Grau-Sepulveda MV, et al. Cost-Effectiveness of Revascularization Strategies: The ASCERT Study. J. Am. Coll. Cardiol. 2015; 65(1): 1-11.Zhang Z, Kolm P, Grau-Sepulveda MV, et al. Cost-Effectiveness of Revascularization Strategies: The ASCERT Study. J. Am. Coll. Cardiol. 2015; 65(1): 1-11.Maganti M, Rao V, Brister S, et al. Decreasing mortality for coronary artery bypass surgery in octogenarians. Can. J. Cardiol. 2009; 25: e32-e35.Maganti M, Rao V, Brister S, et al. Decreasing mortality for coronary artery bypass surgery in octogenarians. Can. J. Cardiol. 2009; 25: e32-e35.Knipp SC, Matatko N, Wilhelm H, et al. Cognitive outcomes three years after coronary artery bypass surgery: relation to diffusion-weighted magnetic resonance imaging. Ann. Thorac. Surg. 2008; 85(3): 872-9.Knipp SC, Matatko N, Wilhelm H, et al. Cognitive outcomes three years after coronary artery bypass surgery: relation to diffusion-weighted magnetic resonance imaging. Ann. Thorac. Surg. 2008; 85(3): 872-9.Hannan EL, Zhong Y, Berger PB, et al. Comparison of Intermediate-Term Outcomes of Coronary Artery Bypass Grafting Versus Drug-Eluting Stents for Patients ≥75 Years of Age. The American journal of cardiology. 2014; 113(5): 803-8.Hannan EL, Zhong Y, Berger PB, et al. Comparison of Intermediate-Term Outcomes of Coronary Artery Bypass Grafting Versus Drug-Eluting Stents for Patients ≥75 Years of Age. The American journal of cardiology. 2014; 113(5): 803-8.Conrotto F, Scacciatella P, D’Ascenzo F, et al. Long-Term Outcomes of Percutaneous Coronary Interventions or Coronary Artery Bypass Grafting for Left Main Coronary Artery Disease in Octogenarians. The American journal of cardiology. 2014; 113: 2007-12.Conrotto F, Scacciatella P, D’Ascenzo F, et al. Long-Term Outcomes of Percutaneous Coronary Interventions or Coronary Artery Bypass Grafting for Left Main Coronary Artery Disease in Octogenarians. The American journal of cardiology. 2014; 113: 2007-12.Alam M, Virani SS, Shahzad SA, et al. Comparison by Meta-Analysis of Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With a Mean Age of >70 Years. The American journal of cardiology. 2013; 112(5): 615-22.Alam M, Virani SS, Shahzad SA, et al. Comparison by Meta-Analysis of Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With a Mean Age of >70 Years. The American journal of cardiology. 2013; 112(5): 615-22.Caughey GE, Vitry AI, Gilbert AL, et al. Prevalence of comorbidity of chronic diseases in Australia. BMC Public Health. 2008; 8: 221. doi:10.1186/1471-2458-8-221.Caughey GE, Vitry AI, Gilbert AL, et al. Prevalence of comorbidity of chronic diseases in Australia. BMC Public Health. 2008; 8: 221. doi:10.1186/1471-2458-8-221.FDA Briefing Document Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee February 10-11, 2014. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/arthritisadvisorycommittee/ucm383180.pdfFDA Briefing Document Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee February 10-11, 2014. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/arthritisadvisorycommittee/ucm383180.pdfGershon A, Croxford R, Calzavara A, et al. Cardiovascular Safety of Inhaled Long-Acting Bronchodilators in Individuals With Chronic Obstructive Pulmonary Disease. JAMA. Intern. Med. 2013; 173(13): 1175-85.Gershon A, Croxford R, Calzavara A, et al. Cardiovascular Safety of Inhaled Long-Acting Bronchodilators in Individuals With Chronic Obstructive Pulmonary Disease. JAMA. Intern. Med. 2013; 173(13): 1175-85.Ogale SS, Lee TA, Au DH, et al. Cardiovascular Events Associated With Ipratropium Bromide in COPD. Chest. 2010; 137(1): 13-9.Ogale SS, Lee TA, Au DH, et al. Cardiovascular Events Associated With Ipratropium Bromide in COPD. Chest. 2010; 137(1): 13-9.Choudhry NK, Fischer MA, Avorn J, et al. The Implications of Therapeutic Complexity on Adherence to Cardiovascular Medications. Arch. Intern. Med. 2011; 171(9): 814-22.Choudhry NK, Fischer MA, Avorn J, et al. The Implications of Therapeutic Complexity on Adherence to Cardiovascular Medications. Arch. Intern. Med. 2011; 171(9): 814-22.

The authors declare that there are no conflicts of interest present.